COST-UTILITY OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COLOMBIA

被引：0
|
作者：
Ojeda, C. [1 ]
Hernandez, N.
Giraldo, C., V [2 ]
Argote, A. C. [3 ]
Coronell, S. [4 ]
Roa, M. [5 ]
机构：
[1] Hosp La Samaritana, Bogota, Colombia
[2] Univ El Bosque, Bogota, Colombia
[3] Hosp San Jose, Bogota, Colombia
[4] Cafesalud Colmed, Bogota, Colombia
[5] Janssen Cilag, Bogota, Colombia
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.506
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS16
引用
收藏
页码：A124 / A124
页数：1
相关论文
共 50 条
  • [1] COST-UTILITY OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COLOMBIA
    Aguirre, A.
    Guerrero, E.
    Hernandez, N.
    Coronell, S.
    Argote, A. C.
    Giraldo, C., V
    Ojeda, C.
    VALUE IN HEALTH, 2017, 20 (05) : A211 - A211
  • [2] COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN SPAIN
    Carrascosa, J. M.
    Vanaclocha, F.
    Caloto, T.
    Echave, M.
    Oyaguez, I
    Tencer, T.
    VALUE IN HEALTH, 2015, 18 (07) : A420 - A420
  • [3] A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
    Colombo, Giorgio L.
    Di Matteo, Sergio
    Peris, Ketty
    Fargnoli, Maria Concetta
    Esposito, Maria
    Mazzotta, Annamaria
    Chimenti, Sergio
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2009, 1 : 53 - 59
  • [4] A COST-UTILITY ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS IN ITALY
    Di Matteo, S.
    Colombo, G. L.
    VALUE IN HEALTH, 2009, 12 (07) : A457 - A457
  • [5] COST UTILITY ANALYSIS OF USTEKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS IN THAILAND
    Tangwongsiri, D.
    Leartsakulpanitch, J.
    VALUE IN HEALTH, 2014, 17 (07) : A782 - A783
  • [6] Cost-utility analysis of Amevive™ (alefacept) in the treatment of patients with moderate-to-severe psoriasis
    Iskedjian, M
    Barkovsky, L
    Desjardins, O
    Walker, JH
    Dorkalam, M
    Shear, N
    Einarson, TR
    VALUE IN HEALTH, 2005, 8 (03) : 331 - 331
  • [7] COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE ITALIAN SETTING
    Barbieri, M.
    Capri, S.
    Oskar, B.
    VALUE IN HEALTH, 2015, 18 (07) : A419 - A420
  • [8] COST EFFECTIVENESS OF TREATMENT WITH ETANERCEPT OR USTEKINUMAB FOR MODERATE TO SEVERE PSORIASIS
    Villacorta, R.
    Hay, J.
    Messali, A.
    VALUE IN HEALTH, 2012, 15 (04) : A103 - A103
  • [9] Ustekinumab for the treatment of moderate to severe psoriasis
    Gospodarevskaya, E.
    Picot, J.
    Cooper, K.
    Loveman, E.
    Takeda, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 61 - 66
  • [10] COST EFFICACY OF USTEKINUMAB IN TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN TURKEY
    Tatar, M.
    Sarioz, F.
    VALUE IN HEALTH, 2010, 13 (03) : A146 - A147
12345